Are you a UK healthcare professional?

Yes No

Join our expert-led promotional meetings

NOV-DEC 2025 / LEEDS, SOUTHAMPTON & LONDON

These promotional, multidisciplinary meetings are organised and funded by Celltrion Healthcare UK Ltd and intended for UK Healthcare professionals only. Celltrion products will be discussed. AE reporting and prescribing information for Omlyclo®▼ (omalizumab) can be accessed here: 75mg and 150mg. 

Register
Agenda

Wednesday, November 12, 2025 - Wednesday, December 3, 2025

Biosimilar Insights & Expanding access in respiratory and dermatology

Join our expert-led promotional meetings to learn more about the role of Omlyclo®▼ (omalizumab) in allergic asthma and chronic spontaneous urticaria.

Please see below for full licensed indications for Omlyclo (omalizumab).

The use of biosimilars is well established in some other disease areas and may provide support for patient access to important treatments.1  The approval of the first respiratory biosimilar of omalizumab provides another treatment option for your suitable patients.2,3

Join us in Leeds, Southampton, or London, where local experts will provide a refresher on the science behind biosimilars and an overview of Omlyclo® (omalizumab).

Speakers

National Speakers

Dr Clive Grattan
Dr Clive Grattan
Consultant Dermatologist, St John's Institute of Dermatology, Guy's and St Thomas' Hospital, London
Prof. Atholl Johnston
Prof. Atholl Johnston
Professor Emeritus of Clinical Pharmacology; Barts and The London School of Medicine and Dentistry; Queen Mary University of London

Local Speakers

Dr Ian Clifton
Dr Ian Clifton
Consultant in Respiratory Medicine; Leeds Teaching Hospitals NHS Trust
Prof. Ratko Djukanovic
Prof. Ratko Djukanovic
Professor of Medicine; University of Southampton
Dr Pujan Patel
Dr Pujan Patel
Consultant Respiratory Physician, Royal Brompton and Harefield Hospital

Who should attend this event?

Healthcare professionals involved in the management of allergic asthma or chronic spontaneous urticaria (CSU).

Where are the events?

There are 3 opportunities to attend a live, in-person event. There is an opportunity to join the Southampton and London events virtually. 

12 November 2025, 17.00 – 20.30

Leeds – Village Hotel, Leeds South

Dr Ian Clifton (Local Speaker), Prof. Atholl Johnston (National Speaker), Dr Clive Grattan (National Speaker)

20 November 2025, 17.00 – 20.30

Southampton – Chilworth Manor Hotel

Prof. Ratko Djukanovic (Local Speaker), Prof. Atholl Johnston (National Speaker) and Dr Clive Grattan (National Speaker)

3 December 2025 , 17.00 – 20.30

London – St Giles Hotel

Dr Pujan Patel (Local Speaker), Prof. Atholl Johnston (National Speaker) and Dr Clive Grattan (National Speaker)

Arrival and registration will take place from 17.00, with buffet food and refreshments available for attendees prior to talks beginning at 17.30

Celltrion Healthcare is an established global biopharmaceutical company, based in South Korea that focuses on biosimilar innovation. Celltrion Healthcare is dedicated to providing accessible treatment options for patients around the world.

Indications for Omlyclo®▼ (omalizumab)2,3

Allergic asthma

Omlyclo® is indicated in adults, adolescents and children (6 to < 12 years of age).

Omlyclo® treatment should only be considered for patients with convincing IgE (immunoglobulin E) mediated asthma (see section 4.2 of the SmPC2,3).

Adults and adolescents (12 years of age and older)

Omlyclo® is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and who have reduced lung function (FEV1 < 80 %) as well as frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.

Children (6 to < 12 years of age)

Omlyclo® is indicated as add-on therapy to improve asthma control in patients with severe persistent allergic asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and frequent daytime symptoms or night-time awakenings and who have had multiple documented severe asthma exacerbations despite daily high-dose inhaled corticosteroids, plus a long-acting inhaled beta2-agonist.

Chronic rhinosinusitis with nasal polyps (CRSwNP)

Omlyclo® is indicated as an add-on therapy with intranasal corticosteroids (INC) for the treatment of adults (18 years and above) with severe CRSwNP for whom therapy with INC does not provide adequate disease control.

Chronic spontaneous urticaria (CSU; Omlyclo® 150mg pre-filled syringe only)

Omlyclo® is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment.

References

(1) NHS England. What Is a Biosimilar Medicine?, 2023. https://www.england.nhs.uk/long-read/what-is-a-biosimilar-medicine/

(2) Celltrion Healthcare UK Limited. Omlyclo 75 mg solution for injection in pre-filled syringe. https://www.medicines.org.uk/emc/product/15916/smpc (accessed Oct 2025).

(3) Celltrion Healthcare UK Limited. Omlyclo 150 mg solution for injection in pre-filled syringe. https://www.medicines.org.uk/emc/product/15917/smpc (accessed Oct 2025).

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or by searching for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Celltrion Healthcare UK Ltd. by emailing UKadverseevents@celltrionhc.com or calling +44 (0) 1753 983500.

If you have any questions about the event, please reach out to the team at events@cogora.com who are responsible for the logistics of these meetings.